Sandoz Clears a Patent Hurdle With Regeneron on Aflibercept Biosimilar On September 9th, Sandoz announced that it had reached an agreement with the patent holder of the reference product Eylea, clearing its way for a launch towards the end of 2026. The agreement with Regeneron halts all patent infringement proceedings against the biosimilar manufacturer. Regeneron … Continue reading Biosimilar Bytes: Sandoz’s Agreement and Organon/Henlius’ Approval